Mersana Therapeutics, Inc.
NaPi2b-targeted antibody-drug conjugates and methods of use thereof

Last updated:

Abstract:

This disclosure provides NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates) that specifically bind to the extracellular region of SLC34A2, and to methods of using such conjugates in a variety of therapeutic, diagnostic, and prophylactic indications.

Status:
Grant
Type:

Utility

Filling date:

13 Mar 2017

Issue date:

16 Mar 2021